A Maintenance Therapy with Differentiating Agents and Low-Dose Chemotherapy Increases Remission Duration and Survival in High Risk AML and MDS Patients.
Dario Ferrero(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Mario Boccadoro(University of Turin), Valentina Giai(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Chiara Maria Dellacasa(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Elisabetta Campa, Mariella Grasso(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Mariella Genuardi, Margherita Bonferroni
Cited by 0
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
|Leukemia|2008|808
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
|New England Journal of Medicine|2023|538